Efficacy of TIGIT in the cancer immune cycle / 中国综合临床

Immunotherapy is a therapeutic method that uses the immune system to inhibit tumor activity and kill tumor cells.It has been proved to be effective in the treatment of various malignant tumors.In general, the immune system can recognize and kill the abnormal cells,while the tumor cells can produce a variety of mechanisms to inhibit the immune system,resulting into the incomplete death of the cells.TIGIT is a type of inhibitory receptor containing T cell immunoglobulin and immunoreceptor protein tyrosine inhibitory motif (ITIM)protein domain.This paper discusses the role of TIGIT in limiting antitumor responses and reviews the mechanisms of action during the cancer immunity cycles.

Effects of tirofiban application time on in-hospital prognosis in patients with acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention / 介入放射学杂志

0.05).Follow-up data showed that there were less angina pectoris attack and higher levels of LVEF in LPG comparing with SPG;showing as 1.26?0.72/day vs 1.75?0.88/day(P=0.040)and 57.2?8.6% vs 52.0?8.5%(P=0.037)respectively.Conclusions Long period application of tirofiban following PCI in patients with STEMI is safe and effective,providing alleviation both on angina pectasis and left ventricular ejectory fraction.(J Intervent Radiol,2007,16:796-798)